Didactics-Unresectable Endometrial Cancer a brief overview

Video Transcription

Video Summary

Dr. Leslie Andriani, a GYN oncologist, discusses the management of unresectable endometrial cancer, covering definitions, presentation, workup, and treatment roles. Key aspects include the use of radiation and systemic therapy for patients unsuitable for surgery. Diagnosis involves imaging, histologic diagnosis, and testing for markers like HER2 and MMR. Unresectable endometrial cancer accounts for 10-15% of cases with poor survival rates. Systemic therapy, often with carboplatin-paclitaxel, is the primary treatment, with the addition of targeted and immunotherapy offering hope for future advancements. Recent clinical trial data (GY-018 and RUBY) shows benefits of adding immunotherapy to standard chemotherapy. HER2-positive cancers may benefit from trastuzumab, and new regimens, including PARP inhibitors, are being explored. Hormonal therapies are considered for specific patients, while the role of neoadjuvant chemotherapy and palliative surgeries are also examined. Future treatment directions involve tailoring therapies based on tumor molecular subtypes.

Asset Subtitle

Leslie Andriani
September 2024

Keywords

unresectable endometrial cancer

systemic therapy

immunotherapy

HER2-positive

clinical trials

molecular subtypes